Can EpiSwitch PSE become more than a diagnostic tool in prostate disease management?
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
What the Trinity Tube reveals about the future of multifunctional devices in NICU care
Can a feeding tube that monitors vitals change neonatal care? See why Neotech is backing this multifunctional device startup.
Medical Devices & Diagnostics
Why FDA’s clearance of ACON’s Flowflex Plus test marks a turning point in home diagnostics
FDA clears Flowflex Plus 4-in-1 test for RSV, flu, and COVID in infants and adults. Find out what this means for diagnostics, families, and industry players.
Medical Devices & Diagnostics
Is Myriad setting a new performance and pricing benchmark in bioscaffold trauma use?
Can Aroa’s bioscaffold platform reshape trauma care economics? See what Myriad’s MASTRR data means for hospitals, surgeons, and reimbursement.
Medical Devices & Diagnostics
Medtronic expands Affera platform with Sphere-360 catheter CE Mark and IDE trial kickoff
Medtronic’s Sphere-360 catheter earns CE Mark and begins U.S. IDE trial. Find out what this means for the future of pulsed field ablation.
Medical Devices & Diagnostics
Nalu Medical’s wearable-powered PNS shows strong 24-month durability in COMFORT RCT
Nalu’s PNS system shows 85% responder rate at 24 months. Find out what this long-term data means for neuromodulation’s future.
Medical Devices & Diagnostics
Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?
Agilent’s new S540MD slide scanner targets scale and AI integration in European pathology labs. Find out what this means for digitisation strategy.
Medical Devices & Diagnostics
Why 60 Degrees Pharmaceuticals is betting on Runway Health to reshape malaria prevention access
Discover how 60 Degrees Pharmaceuticals is using telehealth to expand ARAKODA access and what this shift means for malaria prevention strategy.
Medical Devices & Diagnostics
BioTissue divests surgical and wound care business to BioStem, sharpening focus on ocular regeneration
BioTissue Holdings, Inc. has completed the divestiture of its non-ocular surgical and wound care business to BioStem Technologies, Inc. in a transaction valued at approximately $15 million upfront, with potential earnouts tied to regulatory and commercial milestones. The deal transfers ownership of the Neox and Clarix product lines, along with a seasoned commercial team and
Medical Devices & Diagnostics
Lucid Diagnostics gains strategic VA partnership to deploy EsoGuard across veteran programs
Discover how Lucid Diagnostics is expanding EsoGuard adoption with a new U.S. Veterans Affairs contract for early cancer screening.